Skip to search formSkip to main contentSkip to account menu

ZD 6126

Known as: Vascular Disrupting Agent ZD6126, ZD-6126, ZD6126 
A water-soluble phosphate prodrug of N-acetylcolchinol with potential antiangiogenesis and antineoplastic activities. ZD-6126 is converted in vivo… 
National Institutes of Health

Related topics

Related topics

3 relations
ANG453Microtubule Processfluorouracil/leucovorin calcium/oxaliplatin/ZD6126

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Microtubule targeting agents: mechanisms of action and classification Microtubules are dynamic tubular polymers of α- and β-tubulin which provide structural integrity, promote migration, transport of…
Microtubules are dynamic tubular polymers of αand β-tubulin which provide structural integrity, promote migration, transport of… 
Review
2014
Review
2014
New vascular disrupting agents in upper gastrointestinal malignancies.
Antivascular approaches aim to cause rapid and catastrophic shutdown in the vascular function of the tumour, leading to extensive… 
2012
2012
Enhanced Antitumor Efficacy of a Vascular Disrupting Agent Combined with an Antiangiogenic in a Rat Liver Tumor Model Evaluated by Multiparametric MRI
A key problem in solid tumor therapy is tumor regrowth from a residual viable rim after treatment with a vascular disrupting… 
2010
2010
Präklinische Evaluation des Zytoskelettinhibitors ZD6126 beim humanen Pankreaskarzinom (L3.6pl) nach orthotoper Implantation in die Nacktmaus
Das Pankreaskarzinom ist eine der todlichsten Tumorerkrankungen mit fataler Prognose nach Diagnosestellung. Neben der Frage nach… 
2009
2009
Non-invasive assessment of tumor vessel size in orthotopic prostate tumors and response to the vascular disrupting agent ZD6126
2005
2005
Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
The selective targeting of established tumor vasculature represents an attractive new anticancer drug strategy, distinct from… 
2004
2004
Use of intrinsic-susceptibility magnetic resonance imaging to assess acute tumor response to the vascular-targeting agent ZD6126
2003
2003
Therapie combinee de traitement du cancer
L'invention concerne une methode de traitement d'un cancer a tumeur solide chez un animal a sang chaud, tel qu'un humain. Cette… 
2003
2003
Combination therapy with gemcitabine and zd6126
The present invention relates to a method for the production of a vascular damaging effect in a warm-blooded animal such as a… 
2001
2001
Assessment of the novel tumor vascular targeting agent ZD6126 by non-invasive multi-gradient echo MRI
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)